Cargando…

Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia

Cognitive impairment is a core symptom domain of schizophrenia. The effect of antipsychotics, the cornerstone of treatment in schizophrenia, on this domain is not fully clear. There is some evidence suggesting that antipsychotics may partially improve cognitive function, and that this improvement ma...

Descripción completa

Detalles Bibliográficos
Autores principales:	MacKenzie, Nicole E., Kowalchuk, Chantel, Agarwal, Sri Mahavir, Costa-Dookhan, Kenya A., Caravaggio, Fernando, Gerretsen, Philip, Chintoh, Araba, Remington, Gary J., Taylor, Valerie H., Müeller, Daniel J., Graff-Guerrero, Ariel, Hahn, Margaret K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Psychiatry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290646/ https://www.ncbi.nlm.nih.gov/pubmed/30568606 http://dx.doi.org/10.3389/fpsyt.2018.00622

Ejemplares similares

S89. INVESTIGATING METABOLIC DYSFUNCTION AND METABOLOMIC PROFILE CHANGES IN ANTIPSYCHOTIC NAIVE PATIENTS
por: Costa-Dookhan, Kenya, et al.
Publicado: (2020)

M84. METFORMIN FOR EARLY CO-MORBID PREDIABETES OR DIABETES IN SCHIZOPHRENIA SPECTRUM DISORDERS: A DOUBLE BLIND RANDOMIZED PILOT STUDY
por: Mahavir Agarwal, Sri, et al.
Publicado: (2020)

Pharmacological Interventions to Treat Antipsychotic-Induced Dyslipidemia in Schizophrenia Patients: A Systematic Review and Meta Analysis
por: Kanagasundaram, Pruntha, et al.
Publicado: (2021)

Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health
por: Stogios, Nicolette, et al.
Publicado: (2021)

T231. QUALITY OF LIFE IN ANTIPSYCHOTIC-NAïVE YOUTH: EXPLORING THE INTERPLAY WITH METABOLIC SIDE-EFFECTS
por: Chintoh, Araba, et al.
Publicado: (2020)

Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial
por: Agarwal, Sri Mahavir, et al.
Publicado: (2021)

Metabolomic signatures associated with weight gain and psychosis spectrum diagnoses: A pilot study
por: Lee, Jiwon, et al.
Publicado: (2023)

Outcomes and clinical implications of intranasal insulin on cognition in humans: A systematic review and meta-analysis
por: Wu, Sally, et al.
Publicado: (2023)

Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review
por: Singh, Raghunath, et al.
Publicado: (2022)

Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series
por: Prasad, Femin, et al.
Publicado: (2023)

Associations between plasma clozapine/N-desmethylclozapine ratio, insulin resistance and cognitive performance in patients with co-morbid obesity and ultra-treatment resistant schizophrenia
por: Costa-Dookhan, Kenya A., et al.
Publicado: (2021)

Dimensional distribution of cortical abnormality across antipsychotics treatment-resistant and responsive schizophrenia
por: Itahashi, Takashi, et al.
Publicado: (2021)

Investigating the effects of antipsychotics on brain insulin action: Study protocol for a multi-modality magnetic resonance imaging (MRI) study in healthy controls
por: Stogios, Nicolette, et al.
Publicado: (2022)

F235. DIFFERENTIAL EFFECTS OF ANTIPSYCHOTICS ON NEUROINFLAMMATION AND ENERGY SENSING IN A HYPOTHALAMIC CELL LINE
por: Kowalchuk, Chantel, et al.
Publicado: (2018)

F178. NEUROANATOMICAL PROFILES OF TREATMENT-RESISTANCE IN PATIENTS WITH SCHIZOPHRENIA
por: Plitman, Eric, et al.
Publicado: (2018)

Editorial: Cardiovascular and Physical Health in Severe Mental Illness
por: Agarwal, Sri Mahavir, et al.
Publicado: (2021)

The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment
por: Raben, Alex T., et al.
Publicado: (2018)

Adverse effects of antipsychotics on sleep in patients with schizophrenia. Systematic review and meta-analysis
por: Valencia Carlo, Yarmila Elena, et al.
Publicado: (2023)

S175. AMOTIVATION IS ASSOCIATED WITH SMALLER VENTRAL STRIATUM VOLUMES IN OLDER PATIENTS WITH SCHIZOPHRENIA
por: Caravaggio, Fernando, et al.
Publicado: (2018)

Cortical thinning in relation to impaired insight into illness in patients with treatment resistant schizophrenia
por: Kim, Julia, et al.
Publicado: (2023)

S16. GLUTAMATERGIC NEUROMETABOLITE LEVELS IN PATIENTS WITH TREATMENT-RESISTANT SCHIZOPHRENIA: A CROSS-SECTIONAL 3T PROTON MRS STUDY
por: Iwata, Yusuke, et al.
Publicado: (2018)

Glutathione Levels and Glutathione-Glutamate Correlation in Patients With Treatment-Resistant Schizophrenia
por: Iwata, Yusuke, et al.
Publicado: (2021)

Characterization and prediction of individual functional outcome trajectories in schizophrenia spectrum disorders (PREDICTS study): Study protocol
por: Agarwal, Sri Mahavir, et al.
Publicado: (2023)

Hypofunctional Dopamine Uptake and Antipsychotic Treatment-Resistant Schizophrenia
por: Amato, Davide, et al.
Publicado: (2019)

Influence of antipsychotics on metabolic syndrome risk in patients with schizophrenia
por: Koricanac, Aleksandra, et al.
Publicado: (2022)

Readmission Rates of Patients with Schizophrenia Treated with Depot Antipsychotics versus Oral Antipsychotics in a Community Hospital
por: Espiridion, Eduardo D, et al.
Publicado: (2018)

O9.2. ANTIPSYCHOTIC DRUGS IMPAIR BRAIN GLUCOSE SENSING RESULTING IN WHOLE BODY INSULIN RESISTANCE
por: Castellani, Laura, et al.
Publicado: (2020)

Reduced Insulin Sensitivity Is Related to Less Endogenous Dopamine at D(2/3) Receptors in the Ventral Striatum of Healthy Nonobese Humans
por: Caravaggio, Fernando, et al.
Publicado: (2015)

T192. THE GUT MICROBIOME IN SCHIZOPHRENIA AND ANTIPSYCHOTIC INDUCED METABOLIC DYSFUNCTION
por: Kanji, Sarah, et al.
Publicado: (2018)

Brain Networks Reveal the Effects of Antipsychotic Drugs on Schizophrenia Patients and Controls
por: Towlson, Emma K., et al.
Publicado: (2019)

Antipsychotics-induced improvement of cool executive function in individuals living with schizophrenia
por: Si, Yajing, et al.
Publicado: (2023)

Metformin for the treatment of antipsychotic-induced metabolic disturbances in people with intellectual and developmental disabilities
por: Stogios, Nicolette, et al.
Publicado: (2023)

Antipsychotic Drug Utilization and Adverse Drug Reaction Profiling in Patients With Schizophrenia at a Tertiary Care Hospital in Western India
por: Tripathi, Raakhi K, et al.
Publicado: (2022)

Association of Serotonin(2c) Receptor Polymorphisms With Antipsychotic Drug Response in Schizophrenia
por: Li, Jiang, et al.
Publicado: (2019)

Schizophrenia treatment with a combination of two LAI antipsychotics: A case report
por: Jarosz, Marcin, et al.
Publicado: (2022)

Cognitive Behavioral Therapy for Insomnia as Adjunctive Therapy to Antipsychotics in Schizophrenia: A Case Report
por: Izuhara, Muneto, et al.
Publicado: (2018)

Treatment Responses of Cognitive Function and Plasma Asymmetric Dimethylarginine to Atypical Antipsychotic in Patients With Schizophrenia
por: Yu, Zhi-min, et al.
Publicado: (2019)

Targeting mGlu Receptors for Optimization of Antipsychotic Activity and Disease-Modifying Effect in Schizophrenia
por: Nicoletti, Ferdinando, et al.
Publicado: (2019)

Predictors for Antipsychotic Dosage Change in the First Year of Treatment in Schizophrenia Spectrum and Bipolar Disorders
por: Ringen, Petter Andreas, et al.
Publicado: (2019)

The More, the Merrier…? Antipsychotic Polypharmacy Treatment Strategies in Schizophrenia From a Pharmacology Perspective
por: Hjorth, Stephan
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0qae7lp5fphrb3mlqfttdkp7ie